Skip to Main Content


McGovern to be deputy dean and Yale Medicine CEO

Medicine@Yale, 2022 - May June
by Jill Max


Will play an essential role in the development of clinical strategy for the School of Medicine

Margaret McGovern, MD, PhD, has been appointed deputy dean for clinical affairs at Yale School of Medicine (YSM) and chief executive officer of Yale Medicine (YM). She begins July 1.

McGovern has been Knapp Professor of Pediatrics and dean for clinical affairs at Renaissance School of Medicine at Stony Brook University in New York and vice president of Stony Brook Medicine (SBM) Health System clinical programs and strategy.

Prior to assuming these roles in 2018, she was chair of Pediatrics and physician-in-chief at Stony Brook Children’s Hospital. She led the development and planning of Stony Brook Children’s Hospital and markedly expanded its pediatric clinical research and education programs. McGovern also led the Stony Brook faculty practice plan for six years during her tenure as chair of Pediatrics. In 2019, she led the formation of the SBM Clinically Integrated Network, which is engaged in delivering high-quality, high-value care by building a population health platform. She has served as the physician executive leader for the initiative.

McGovern received her PhD in genetics from the Mount Sinai Graduate School of Biomedical Sciences and her MD from Mount Sinai School of Medicine (now called Icahn School of Medicine at Mount Sinai). She completed her residency training in pediatrics and fellowships in clinical and molecular genetics at Mount Sinai Hospital before joining the faculty.

At Mount Sinai, she was vice chair of the Department of Genetics and Molecular Medicine and professor of human genetics, and of oncological sciences and obstetrics and gynecology. She was the pro- gram director for the NIH-funded General Clinical Research Center (GCRC) and carried out CDC- and NIH-funded research focused primarily on the integration of molecular genetic diagnostic testing into clinical practice and inborn errors of metabolism. She is considered a world authority on sphingolipidoses.

At Yale, McGovern will play an essential role in the development of clinical strategy for the School of Medicine at an important juncture in the relationship between YSM and Yale New Haven Health System. She will provide strategic counsel and otherwise work to realize YSM’s vision for its clinical enterprise.

As CEO of YM, she will participate actively in the senior leadership group of the medical school’s aca- demic health system and play a key role in setting and realizing strategic goals. As deputy dean for clinical affairs, she will serve as the physician leader who represents the clinical mission of the School of Medicine in all venues. In this role, she will work closely with the clinical chairs in the recruitment of clinical faculty, mentor the next generation of clinical leaders, and collaborate with the deputy deans of research and education to balance the needs for enhancing the academic and educational missions of YSM with clinical ambulatory operational efficiencies, quality improve- ment, and sound clinical finances.